Death rates for patients hospitalized with COVID-19 have decreased in Minnesota since the start of the pandemic, as doctors have gained new drugs and understanding of how to treat the infectious disease.
A COVID-Net report provided this week by the Minnesota Department of Health examined outcomes of 4,356 patients hospitalized with COVID-19 through July and found that 12% had died, compared with an earlier report in May showing that 15% had died. Among those requiring intubation or the use of heart-lung machines due to breathing problems and complications from COVID-19, the death rate declined from 53% in the May report to 37%.
Doctors said these trends reflect progress made since the start of the pandemic, when there were no proven treatments for COVID-19, to a summer in which new drugs and therapies are emerging.
"It does feel like that is helping and there are fewer patients who are progressing from needing a little bit of oxygen to going all the way to the ICU," said Dr. Greg Siwek, an infection-prevention physician at Regions Hospital in St. Paul.
Treatments include dexamethasone, a steroid given to hospitalized patients that reduces the overreaction by the immune system that can be more lethal than the infection itself.
Supplies of the antiviral remdesivir have increased to the point that the drug is in broad use in Twin Cities hospitals, often in combination with steroids and experimental infusions of virus-fighting antibodies from the plasma of recovered patients.
Except for a spike in cases in late May — when more than 600 hospital beds were filled with COVID-19 patients — the pandemic hasn't caused the surges in Minnesota that overwhelmed hospitals in China and Italy at the earliest stages of the pandemic and in New York this spring.
A guiding premise of Gov. Tim Walz's pandemic response, including a 51-day statewide shutdown in the spring, was to delay and reduce COVID-19 case growth that could overwhelm hospitals.